Convergen Secures $15 Million Seed+ Financing to Advance Therapeutics for Protein Aggregation Diseases
SUZHOU, China, Aug. 31, 2026 /PRNewswire/ -- Convergen, a biotechnology company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, today announced the closing of a $15 million Seed+ financing round. This round was led by MPCi, with participation from LAV, BioTrack Capital and a leading biotech...
T-MAXIMUM B7-H3-Targeted Allogeneic CAR-T Therapy MT027 Receives FDA Fast Track Designation, Accelerating Global Development for Intracranial Solid Tumors
MT027 has previously been granted FDA Orphan Drug Designation and has entered Phase II clinical development in recurrent glioblastoma BEIJING, Aug. 31, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL Inc. ("T-MAXIMUM") today announced that its investigational allogeneic CAR-T cell therapy MT027 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent...
Samsung Biologics publishes prospectus for PolyPeptide public tender offer
Direct subsidiary Samsung Peptide AG acting as formal offeror of the public tender offer Publication of offer prospectus follows pre-announcement on July 20, 2026 Largest individual shareholder committed to tender all of its PolyPeptide shares into offer Main offer period expected to last from Sept. 15 to Oct. 12, 2026...
SIBIONICS Showcases GS3 in Melbourne, Advancing More Efficient, AI-Powered Glucose Monitoring
MELBOURNE, Australia, Aug. 31, 2026 /PRNewswire/ -- SIBIONICS showcased its sensor innovation and AI-powered glucose monitoring at the joint IDF-WPR, ADC and Metabolic Diseases 2026 congress, held in Melbourne from 18–21 August. Through Booth #1, a scientific symposium and on-site interviews with Credentialled Diabetes Educators (CDEs), the company brought together advanced technology, clinical evidence and real-world perspectives. ...
HUAWEI WATCH D3 Makes Early Debut at ESC Congress 2026: A New Era in Wrist-Based Blood Pressure Management
MUNICH, Aug. 31, 2026 /PRNewswire/ -- The European Society of Cardiology Congress (ESC Congress 2026), one of the world's most influential academic gatherings in cardiovascular medicine, officially kicked off today in Munich, Germany. Huawei showcased its latest innovations in health and fitness, offering an exclusive sneak peek at its next-generation ambulatory blood pressure monitor, the HUAWEI WATCH D3,...
Chula Researchers Develop Synthetic Boar Scent Mimicking Natural Pheromones to Reduce Disease Outbreak Risks in Pig Farms
BANGKOK, Aug. 31, 2026 /PRNewswire/ -- Researchers from Chulalongkorn University's Faculty of Veterinary Science have developed synthetic boar scent mimicking natural pheromones, providing a safer way to stimulate reproduction while reducing the risk of disease transmission associated with direct contact between breeding animals. Chula Researchers Develop Synthetic Boar Scent Mimicking Natural Pheromones to Reduce Disease Outbreak Risks...
Amai Proteins’ sweelin® Approved for Sale in Israel, Opening the Market to a New Generation of Reduced-Sugar Food and Beverage Products
Third regulatory approval in less than six months enables food and beverage manufacturers to commercialize products sweetened with sweelin® in Israel. REHOVOT, Israel, Aug. 31, 2026 /PRNewswire/ -- Amai Proteins announces that the Israeli Ministry of Health has officially approved sweelin® as a novel food ingredient for use in a broad range of food and beverage products. Food...
Subsidised Access to Columvi® Now Available for Eligible Patients with Relapsed or Refractory DLBCL in Singapore
Columvi (glofitamab) will be added to the Cancer Drug List (CDL) and Medication Assistance Fund (MAF) on 1 September 2026 for eligible patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for autologous stem cell transplant and have received at least one prior therapy. This...
WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion
SHANGHAI, Aug. 31, 2026 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), announces the distribution of its 2026 interim cash dividend. Building on its inaugural interim dividend of RMB 1.03 billion in 2025, the Company has further increased its 2026 interim dividend payout to RMB 1.51...
Data4Life and Monash Health Announce Strategic Collaboration to Advance Clinical Research
Data4Life and Monash Health have partnered to optimize clinical trial design and execution, complemented by educational workshops and professional training programs, with a shared commitment to improving patient outcomes. - Picture is available at AP - MELBOURNE, Australia, Aug. 31, 2026 /PRNewswire/ -- Monash Health, the largest public health service in Victoria, Australia, has signed a Memorandum of Understanding...
